Who was studied?
One patient with a large SMARCA4-deficient undifferentiated cervical tumor.
What does the publication report?
Tumor shrinkage, symptom relief and PFS exceeding 12 months were reported. The contribution of each treatment cannot be separated.
Safety findings
Treatment was described as tolerated, but the abstract does not supply a full graded event table.
How should we interpret it?
A single patient cannot establish efficacy or predict an individual outcome. Prior and concurrent treatments limit attribution.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report · DOI: 10.3389/fimmu.2026.1826847 · PMID: 42183247
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.